POPULARITY
30 episodes with AAV
19 episodes with AAV
12 episodes with AAV
12 episodes with AAV
8 episodes with AAV
9 episodes with AAV
12 episodes with AAV
12 episodes with AAV
9 episodes with AAV
10 episodes with AAV
8 episodes with AAV
9 episodes with AAV
6 episodes with AAV
9 episodes with AAV
6 episodes with AAV
6 episodes with AAV
5 episodes with AAV
4 episodes with AAV
6 episodes with AAV
6 episodes with AAV
5 episodes with AAV
5 episodes with AAV
4 episodes with AAV
6 episodes with AAV
3 episodes with AAV
5 episodes with AAV
4 episodes with AAV
4 episodes with AAV
4 episodes with AAV
4 episodes with AAV
4 episodes with AAV
3 episodes with AAV
3 episodes with AAV
4 episodes with AAV
17 episodes with AAV
2 episodes with AAV
In a truly stunning, out-of-left-field event, the Giants traded for slugger Rafael Devers. It really did come out of nowhere, but it's genesis was the discontent that was brewing in Boston after Devers was not being treated like a franchise player, being promised third base, only to have Alex Bregman usurp it. The Giants gave up relatively little as a price for securing Devers for the next 8 1/2 years. This was not a rental, and often 2 month rentals end up costing teams a LOT more than what the Giants gave up. All told, the Giants traded away Kyle Harrison, Jordan Hicks, and two prospects. Even the AAV for Devers is under what the market would bear now and certainly what it will bear in several years. Devers is in the prime of his career at age 28. Buster Posey made this happen, and he is the man right now. Eric, Willie, and Chad discuss this blockbuster and can't find a comp to it in recent Giants history. We are all excited, but if the Giants would just actually perform on the field. After briefly tying the Dodgers for first place in the NL West over the weekend, they have lost 4 in a row and 5 of 6 overall. Let's hope they snap out of it with the help of their new shiny star.@torturecastfacebook.com/torturecasttorturecast.com
One of the challenges of delivering gene therapies to the eye is that once a subretinal injection is made, the therapy's distribution is confined to the margins of the pocket of fluid that is created, known as a bleb. Atsena, which is developing gene therapies for X-linked retinoschisis and Leber congenital amaurosis 1, uses its AAV.SPR technology that allows the gene therapy to spread laterally after injection. We spoke to Patrick Ritschel, CEO of Atsena Therapeutics, about the challenges of gene therapies for inherited retinal diseases, how the company's unique vector technology addresses this, and how it allows for safer and more effective delivery of gene therapies to the retina.
The Stanley Cup Final loss still stings, but the focus has now fully shifted to the future. On today's edition of Oilersnation Everyday, Tyler, Liam, and Producer Bordzy dissect what's shaping up to be a pivotal offseason for the Edmonton Oilers.Will Connor McDavid commit long-term and sign an extension this summer? Could the team explore moving on from Darnell Nurse and his hefty cap hit after another frustrating playoff run? These are just a few of the major questions we'll try to answer on the show.We'll also project what next season's lineup could look like and explore some possible offseason moves — especially in net. Is Stuart Skinner still the guy? And if so, who could the Oilers bring in to form a more reliable tandem?Plus, we'll break down the news of the weel: Will Trent Frederic stay in Edmonton? The Oilers and Frederic have been linked to an 8-year extension with an AAV of $4 million per season. We'll give our thoughts on the potential deal, what it could mean for the team's cap structure moving forward, and why management feels Frederic was a long-term fit for this core.We're also joined by What Chaos! host DJ Bean to get his perspective on the Oilers' playoff run, the sting of back-to-back Stanley Cup Final losses, and what Edmonton needs to prioritize if they want to finally get over the hump next season.It's a loaded offseason edition of the show — let's get into it.Website: https://oilersnation.com/ https://twitter.com/OilersNation/ https://www.youtube.com/@Oilersnationdotcom/ https://www.facebook.com/OilersNation/https://www.instagram.com/oilersnationdotcomhttps://www.tiktok.com/@oilersnation SHOUTOUT TO OUR SPONSORS!!
Ben and Brent continue the hockey talk into the final hour on Monday. The hosts welcome on Daily Faceoff insider, Frank Seravalli, to break down the Stanley Cup Final. He debates if Edmonton's goaltending situation is one of the main reasons they're a game away from losing the championship in consecutive years. They then look ahead to the upcoming free agent market and parse through some of the top names set to hit the market. They discuss if Brad Marchand could get a higher AAV than Sam Bennett and what Mitch Marner will be seeking. The morning duo then check in with Blue Jays Central analyst, Madison Shipman (28:55), to talk about Toronto's MLB team and how they can reset returning to Rogers Centre this week after getting swept to close out their road trip. The trio discuss Vladimir Guerrero Jr.'s tendency to walk over hitting for power, as well as what has made Alejandro Kirk so consistent and productive this season.The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Sports & Media or any affiliates.
BSR has published a new set of management recommendations for ANCA-associated vasculitis (AAV), serving as an update to our AAV guideline last published in 2017.Find out more via our blog. Join guideline working group Chair, Lorraine Harper, and group members Rosemary Hollick, Harold Wilson-Morkeh, Georgina Ducker and expert by experience member, Zoi Anastasa, in a roundtable discussion hosted by Prof Ernest Choy, Editor in Chief of Rheumatology to find out what is included in the publication and what has changed since the 2017 guideline was published. Sign up for the BSR educational webinars to accompany the recommendations here: https://www.rheumatology.org.uk/events-learning/webinars/updated-recommendations-for-managing-anca-associated-vasculitis Read the full guideline and download the summary pdf here. Thanks for listening to Talking Rheumatology! Join the conversation on X using #TalkingRheum or tweet us @RheumatologyUK.BSR is the UK's leading specialist medical society for rheumatology and MSK health professionals. To discover how we can support you in delivering the best care for your patients, visit our website.
Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, AppleTV or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?Nicole: Willingness to take bold leaps and embrace the unknown.Imagine a world where cancer is as treatable as the flu. That's the vision Nicole Paulk, the founder and CEO of Siren Biotechnology, is working tirelessly to bring to life. Driven by groundbreaking science, Nicole's company is on the brink of launching clinical trials for a revolutionary cancer treatment.Nicole's work leverages engineered viruses—those that don't make you sick—to deliver genetic medicines directly to cancer cells. These “good viruses” act as a delivery system for anti-tumor drugs, targeting difficult-to-treat cancers like recurrent high-grade gliomas, a fatal brain cancer. “We started to see data that looked really promising in this space,” Nicole explained, adding, “We felt a moral obligation to go after this cancer where there's just this huge unmet need.”Siren Biotechnology's approach is designed to have broad applications. Unlike treatments that target specific genetic mutations, their method has the potential to work on various tumor types. Nicole describes it as using viruses like a “little FedEx delivery truck” that can be engineered to deliver medicine precisely where it's needed in the body.This innovation didn't happen overnight. Nicole, a former professor of virology at UCSF, took the bold step of leaving academia to launch Siren Biotechnology. “I decided to resign from my faculty position and go be the founder and CEO just because I was so excited about the data and what we had so far,” she shared.In addition to traditional venture capital funding, Siren Biotechnology is inviting the public to invest through a regulated investment crowdfunding campaign. This unique opportunity allows patients, families, and supporters touched by cancer to be part of their journey. “We wanted to bring patients and their families onto our cap table,” Nicole said. “It's a way to involve them in the conversation much earlier.”Siren Biotechnology's work could redefine cancer care and inspire a new model for patient-centered innovation. With clinical trials just months away, the future looks brighter for those battling cancer—and for all of us who dream of a world where cancer is no longer a death sentence.tl;dr:Nicole Paulk's Siren Biotechnology transforms viruses into targeted cancer therapies with universal potential.The company focuses on recurrent high-grade gliomas, a fatal brain cancer with no standard treatment.Nicole left academia to lead Siren, leveraging her groundbreaking virology research to launch the company.Siren's unique crowdfunding campaign lets patients and families invest in the fight against cancer.Nicole's superpower, fearless innovation, drives her bold mission to revolutionize cancer care.How to Develop Fearless Innovation As a SuperpowerNicole's superpower is her willingness to take bold leaps and embrace the unknown. After spending nearly two decades building her academic career, Nicole left her position as a virology professor at UCSF to start Siren Biotechnology. She explained, “I feel like my superpower is just kind of being willing to jump off the cliff without a parachute and be like, we're going to figure it out. We're going to make it work.”Nicole exemplified fearless innovation when her research led to a groundbreaking discovery about the biology of a virus, one that required rewriting existing textbooks. Initially met with skepticism, her work was later validated and became a foundation for Siren Biotechnology's cancer treatment. This pivotal moment highlights Nicole's courage to challenge conventional knowledge and pursue transformative ideas.Tips for Developing This Superpower:Be willing to question conventional wisdom and explore new paths.Take calculated risks, even if it means stepping away from a well-defined career path.Embrace discomfort and uncertainty as a necessary part of innovation.Engage others by communicating your vision in relatable and accessible ways.By following Nicole's example and advice, you can make fearless innovation a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileNicole Paulk (she/her):CEO, Founder, President, Siren BiotechnologyAbout Siren Biotechnology: We are combining two transformative therapeutic technologies – AAV gene therapy and cytokine immunotherapy – into a single, reimagined modality that overcomes key challenges and redefines how we destroy tumor cells and elicit anti-tumor immunity.This is the first AAV gene therapy drug product that can be made once and used in numerous indications – a huge leap forward for the field. This drastically reduces clinical development times, manufacturing timelines, and capital needs for each clinical trial. Most importantly, ‘universal' means countless solid tumor cancer patients – regardless of tumor type or mutations – may benefit from this breakthrough approach.Website: sirenbiotechnology.comX/Twitter Handle: @SirenBioCompany Facebook Page: facebook.com/SirenBiotechnologyOther URL: wefunder.com/siren.biotechnologyBiographical Information: Dr. Nicole Paulk is the CEO, Founder, and President of Siren Biotechnology and has dedicated her career to advancing the field of gene therapy. With nearly two decades of expertise, Nicole has been at the forefront of developing cutting-edge advances to propel the field of gene therapy forward for a wide range of diseases.Before founding Siren, Nicole held various leadership positions in academia and industry and most notably was an Assistant Adj Professor of AAV Gene Therapy in the UCSF Department of Biochemistry & Biophysics before leaving to found Siren. Nicole has a B.S. in Medical Microbiology, a Ph.D. in Viral Gene Therapy and Regenerative Medicine from OHSU, and completed her Postdoctoral Fellowship and Instructorship in Human Gene Therapy at Stanford University prior to starting her lab at UCSF. Nicole is a pioneer in the development of next-generation AAV platforms for gene repair, gene transfer and gene editing, directed evolution for novel engineered capsid evolution, and comparative multi-omic approaches to interrogate translational AAV biology.Nicole is a renowned expert in gene therapy and has consulted extensively for big pharma, written draft CMC guidance for the FDA, and sits on the Scientific Advisory Boards for Sarepta, Astellas, Metagenomi, Dyno Therapeutics, CEVEC, GRO Biosciences, Excision BioTherapeutics, WhiteLab Genomics, Johns Hopkins Gene Therapy Initiative, the Gene Therapy for Rare Disorders Searchlight Program, and several stealth startups. She has been quoted in The Wall Street Journal, The Economist, The Boston Globe, Endpoints, STAT, Phacilitate, GEN, BioPharma Dive, Evaluate Vantage, SF Business Times, WIRED, Drug Discovery World, MIT Tech Review, C&EN, and more. She sits on the Scientific Editorial Boards of the journals Gene Therapy, Human Gene Therapy, and Biopharma International Gene Therapy. She is the Chair of the American Society of Gene and Cell Therapy (ASGCT) Translational Science Committee, and a member of the ASGCT Cancer Cell and Gene Therapy Committee and the Biocom California Cell and Gene Therapy Committee. She has invented numerous AAV gene therapy technologies that have been shared or licensed to dozens of gene therapy companies and nonprofit groups working in rare diseases.Outside of work, you can find Nicole adventure traveling (think whitewater rafting meets backcountry trekking), snowboarding, planning elaborate Halloween parties complete with animatronics and ghoulish menus, tending her vegetable garden, and obsessing over the latest wearable gadgets. If you're trying to track her down at a conference and can't find her, it's because she snuck off to an oyster bar.X/Twitter Handle: @Nicole_PaulkLinkedin: linkedin.com/in/nicolepaulkInstagram Handle: @sirenbioSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include FundingHope, Kingscrowd and Crowdfunding Made Simple. Learn more about advertising with us here.Max-Impact MembersThe following Max-Impact Members provide valuable financial support:Carol Fineagan, Independent Consultant | Lory Moore, Lory Moore Law | Marcia Brinton, High Desert Gear | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Ralf Mandt, Next Pitch | Scott Thorpe, Philanthropist | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on June 17, 2025, at 1:00 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.SuperCrowdHour, June 18, 2025, at 12:00 PM Eastern. Jason Fishman, Co-Founder and CEO of Digital Niche Agency (DNA), will lead a session on "How to Spin $1 of Advertising into $10!" He'll reveal proven strategies and marketing insights drawn from years of experience helping successful crowdfunding campaigns. Whether you're a founder planning a raise or a supporter of innovative startups, you'll gain actionable tips to boost visibility, drive engagement, and hit your funding goals. Don't miss it!Join us on June 25, 2025, at 8:00 PM Eastern for the Superpowers for Good Live Pitch—streaming on e360tv, where purpose-driven founders take the virtual stage to present their active Regulation Crowdfunding campaigns to a national audience of investors and changemakers. Selected startups are chosen for their commitment to community, alignment with NC3's Community Capital Principles, and their drive to create real-world impact. Thanks to sponsors DNA and DealMaker, this event is free to watch and amplifies the voices of underrepresented and mission-aligned entrepreneurs. Don't miss this inspiring evening where capital meets purpose—tune in to discover and support the next wave of impact-driven innovation.SuperCrowd25, August 21st and 22nd: This two-day virtual event is an annual tradition but with big upgrades for 2025! We'll be streaming live across the web and on TV via e360tv. Soon, we'll open a process for nominating speakers. Check back!Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Devin Thorpe is featured in a free virtual masterclass series hosted by Irina Portnova titled Break Free, Elevate Your Money Mindset & Call In Overflow, focused on transforming your relationship with money through personal stories and practical insights. June 8-21, 2025.Join Dorian Dickinson, founder & CEO of FundingHope, for Startup.com's monthly crowdfunding workshop, where he'll dive into strategies for successfully raising capital through investment crowdfunding. June 24 at noon Eastern. Regulated Investment Crowdfunding Summit 2025, Crowdfunding Professional Association, Washington DC, October 21-22, 2025.Call for community action:Please show your support for a tax credit for investments made via Regulation Crowdfunding, benefiting both the investors and the small businesses that receive the investments. Learn more here.If you would like to submit an event for us to share with the 9,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe
In honor of Molecular Therapy’s 25th anniversary, this episode is the second in a series hosted by Dr. Joseph Glorioso, Editor-in-Chief of Molecular Therapy, that will cover comprehensive reviews of critical developments in the field of gene and cell therapy over the past 25 years. In this episode, Dr. Glorioso will discuss the reviews, AAV vector development, back to the future, with author Sheila Mikhail; M34, Inc.; and The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy; with author Dr. Mark Kay, Stanford University. If you enjoy this deep dive into research that is critical to the field, check out two more ASGCT events happening this fall: Advancing Cell and Gene Therapies for Cancer and Breakthroughs in Targeted In Vivo Gene Editing. During these events – in October and November, respectively – you’ll be able to hear directly from researchers about their own work related to these topics, or you can submit your own abstract for possible presentation. We hope to see you there! Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.
The Colorado Avalanche have locked in their 2C with Brock Nelson signing a three year $7.5 million AAV contract with the team. The First piece to the Avs postseason puzzle is set, what does mean for the Avs and what comes next? Intro - 0:00First reactions - 1:00Skating Data - 6:25High danger scoring - 20:35A bit much? - 31:30Still some work to be done, but..- 38:00Where's the snarl? - 58:15Wrapping up - 1:02:00 An ALLCITY Network Production PARTY WITH US: https://thednvr.com/events ALL THINGS DNVR: https://linktr.ee/dnvrsports MERCH: https://store.allcitynetwork.com/collections/dnvr-locker SUBSCRIBE: https://www.youtube.com/c/DNVR_Sports Toyota: Visit Your Front Range Toyota Stores at a location near you - Toyota is the official vehicle of DNVR. Toyota - Let's Go Places! First Bank: So, if you're ready for better banking and the chance to earn a little extra, head to efirstbank.com/bonus. Certain restrictions and requirements apply. Member FDIC. Hall of Fame App: Get a 7-Day Free Trial + 50% Off your first month with code DNVR. Just download the HOF app on iOS and Android or visit www.hofbets.com, enter code DNVR, and you're all set. #ad Monarch Money: Use Monarch Money to get control of your overall finances with 50% off your first year at https://www.monarchmoney.com/dnvr bet365: Go to https://www.bet365.com/hub/en-us/app-hero-banner-1?utm_source=affiliate&utm_campaign=usapp&utm_medium=affiliate&affiliate=365_03485318 or use code DNVR365 when you sign up. Must be 21+ and physically located in CO. Please gamble responsibly. If you or someone you know has a gambling problem and wants help call or TEXT 1-800-GAMBLERUCHealth: Learn more about Living Like There's A Tomorrow at https://www.uchealth.org/tomorrow/?utm_source=DNVR&utm_medium=Audio&utm_campaign=Brand_LLTIAT_Null_JFMFY25_AW_Null Coors Light: Delivery on Instacart at https://coorslight.com/DNVR. Celebrate Responsibly. Coors Brewing Company, Golden, Colorado. Gametime: Download the app, create an account, and use code DNVR for $20 off your first purchase. Terms apply. Shady Rays: Head to https://shadyrays.com and use code: DNVR for 35% off polarized sunglasses. Try for yourself the shades rated 5 stars by over 300,000 people. Get 10 FREE meals at https://hellofresh.com/freeavalanche. Applied across 7 boxes, new subscribers only, varies by plan. https://www.bet365.com/hub/en-us/app-hero-banner-1?utm_source=affiliate&utm_campaign=usapp&utm_medium=affiliate&affiliate=365_03485318 or use code DNVR365 when you sign up. Must be 21+ and physically located in CO. Please gamble responsibly. If you or someone you know has a gambling problem and wants help call or TEXT 1-800-GAMBLER When you shop through links in the description, we may earn affiliate commissions. Copyright Disclaimer under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education and research. Fair use is a use permitted by copyright statute that might otherwise be infringing.#coloradoavalanche #hockey #hockeypodcast
We have another busy day to get through all the Philadelphia Flyers news and rumors floating around.First, Noah Cates is Danny Briere's most recent piece of business, signing an extension today for 4 years with a $4 million AAV.Also, Roger McQueen has said he's 10/10 healthy following a misdiagnosis of his back injury. If the 6-5 center prospect is truly 100%, can the Flyers afford to pass on him if available at #6?There's also Charlie's first Mock Draft, a Brent Flahr Q&A in the Inquirer, and more!
In this episode of the BroadEye Podcast, hosts Shawn Maloney and Dr. Bruno Fernandes welcome Prof. Michel Michaelides, one of the most active clinical researchers in ophthalmology today. Prof. Michaelides leads a large inherited retinal disease clinic—seeing 30–40 children and adults each week—and splits her time between patient care, advanced imaging research, and steering more than ten ongoing clinical trials. Why This Matters Inherited retinal diseases affect hundreds of thousands worldwide, and for most there is still no approved treatment. Over the past two years, we've seen multiple Phase 1/2 gene-therapy trials move into registrational studies, alongside novel antioxidant approaches and AI-driven biomarkers. Today's conversation cuts through the jargon to give you a clear picture of where the field stands—and where it's headed. Key Takeaways Beyond RPE65: While Luxturna paved the way, newer AAV-based therapies for X-linked RP (RPGR) and other targets are now in Phase 2 and Phase 3 trials, with early data showing promising safety and efficacy. Imaging & Function: Prof. Michaelides is pioneering next-generation retinal imaging devices and novel functional assays to capture meaningful changes in vision—critical for shortening trial timelines. Antioxidant Strategies: High-dose N-acetylcysteine trials are under way, offering a non-viral approach to slow photoreceptor degeneration across multiple genetic subtypes. AI in Stratification: Machine-learning algorithms on retinal scans can help predict progression rate and identify the best candidates for specific therapies, improving both trial design and patient outcomes. Balancing Dose & Safety: Finding the sweet spot between transgene expression and immune activation remains a core challenge—Prof. Michaelides shares lessons learned from dose-escalation cohorts. Phase 3 & Beyond: With over a hundred patients enrolled in pivotal studies, we're closing in on potential approvals—but long-term follow-up and real-world evidence will determine ultimate impact. About the Guest Prof. Michelle Michaelides is a clinician-scientist specializing in inherited retinal diseases. She leads dedicated adult and pediatric IRD clinics, oversees the development of advanced imaging and functional biomarkers, and serves as principal investigator on over ten clinical trials spanning gene therapies, antioxidant agents, and AI-guided stratification tools. Prof. Michaelides regularly lectures at international conferences and collaborates with industry and academic partners to accelerate the translation of research into real-world treatments.
In this latest episode of the BroadEye podcast, hosts Shawn Maloney and Dr. Bruno Fernandes sit down with Dr. Arshad M. Khanani, MD, MA, FASRS, a pioneer in vitreoretinal gene-therapy trials and Managing Partner at Sierra Eye Associates. Dr. Khanani shares front-line insights into how genetic medicines are reshaping treatment for inherited and degenerative retinal diseases, highlighting both the promise and the practical challenges of bringing one-time therapies to patients. Why Gene Therapy Matters Today Recent years have seen the first US approvals of in-vivo retinal gene therapies, beginning with voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophy in December 2017. These one-off treatments offer durable vision improvements where none existed before, but they also raise questions of long-term safety, vector delivery, and equitable access. Dr. Khanani's Journey With over a decade leading surgical trials in sustained-delivery and viral-vector therapies, Dr. Khanani has overseen early human work on next-generation agents—including subretinal injections of AAV vectors and novel capsid designs. He describes lessons learned from Phase 1 safety studies through global registrational trials, emphasizing iterative “vector evolution” to boost efficacy and minimize inflammation. Key Takeaways Vector Optimization: Directed-evolution platforms are accelerating discovery of capsids that target photoreceptors more precisely, reducing off-target toxicity. Durability vs. Dose: Striking the right balance between transgene expression and immune activation remains central—higher doses don't always equal better outcomes. Regulatory Pathways: While Luxturna set a precedent, streamlined FDA and EMA guidance on trial endpoints and real-world evidence will shape the next wave of approvals. Cost & Access: Innovative payment models (e.g., outcomes-based installment plans) are emerging to address the multi-hundred-thousand-dollar price tags of these therapies. About the Guest Dr. Arshad M. Khanani, MD, MA, FASRS, is a vitreoretinal surgeon, researcher, and Managing Partner at Sierra Eye Associates in Reno, Nevada. He holds dual degrees in medicine and medical humanities from the University of Nevada, Reno, and is a fellow of the American Society of Retina Specialists. Dr. Khanani has authored over 100 peer-reviewed articles on retinal disease and served as principal investigator on more than 30 clinical trials of gene and cell therapies for inherited and age-related retinal disorders. He also lectures internationally on surgical innovation, vector design, and the economics of advanced ocular treatments.
In a major scientific breakthrough, researchers from 29 institutions across North America—led by the Allen Institute—have developed over 1,000 new genetic tools called enhancer AAV vectors to precisely target specific brain cells. Guest: Dr. Bosiljka Tasic - Director of Molecular Genetics at the Allen Institute for Brain Science Learn more about your ad choices. Visit megaphone.fm/adchoices
Sunday May 18, 2025. Week 21 Show notes on the site: https://curesyngap1.org/podcasts/syngap10/ CAMP4 Press Release https://investors.camp4tx.com/news-releases/news-release-details/camp4-presents-translational-data-syngap1-related-disorders Dr. Yuri at WODC: https://www.youtube.com/watch?v=oNwgo7TmrVo Presentation at ASGCT: https://investors.camp4tx.com/news-events/presentations GETA Talk: https://www.facebook.com/Syngapresearch/posts/pfbid08Aztex32vdwNZduVkPQeG353W49Dhq8iKJeZEkajKUmkeUiDdCwzyqa9ndEVpdCUl To get these Therapies to kids the NHS data is key, ProMMis CHOP - Email them ENDD@chop.edu Stanford (Singed!) - https://curesyngap1.org/blog/srf-announces-stanford-launches-california-synaptopathy-clinic/ CHCO - https://curesyngap1.org/blog/visiting-syngap1-natural-history-study-childrens-hospital-colorado-chco/ Citizen Health https://cureSYNGAP1.org/Citizen is at 267, why not 300? Hopkins article featuring SRF - Competition is good for the patient FB https://www.facebook.com/cureSYNGAP1/posts/pfbid07MP7St3zdxLKYXTJULKa5S35YvgL6AJndenHicedxU3rtQF6iY1wwwNUoDuUD9cpl LI https://www.linkedin.com/posts/curesyngap1_nih-cuts-stalling-progress-on-rare-genetic-activity-7328449817074946048-AAsB ASGCT Mouse poster for Q504X from the JAX, Dr. Matt Simon Conf Video https://www.youtube.com/watch?v=loYXkkTSUIY Presentation on AAV for SYNGAP1 at Allen by Dr. Megan Quinlan What about this guy? Gift link: https://www.nytimes.com/2025/05/15/health/gene-editing-personalized-rare-disorders.html?unlocked_article_code=1.H08.E-oX.t5bo6kxJGUOU&smid=url-share PBS: https://www.youtube.com/watch?v=dOeiPoa3gvM Eric Topol: https://erictopol.substack.com/p/the-first-human-to-undergo-in-vivo More incredible news https://news.unl.edu/article/husker-team-wins-second-round-prize-in-nih-gene-editing-challenge REPURPOSING Mike's post in private SRF Group: https://www.facebook.com/groups/syngap #Amlexanox with Fortuity Pharma. https://fortuitypharma.com/ Butyrate Update https://aesnet.org/abstractslisting/phenylbutyrate-for-syngap1-related-developmental-and-epileptic-encephalopathy Trial ending at year end, working with SLC6A1 and Rachel Heilmann to continue coverage, then we can scale, once we have a paper. SunButyrate https://a.co/d/7kiHXS8 PUBMED 328 total with 20 YTD https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&sort=date&sort_order=asc&timeline=expanded Sleep https://www.sciencedirect.com/science/article/abs/pii/S1389945724005793?via%3Dihub SRF Fundraisers MDBR with AJH and HM https://curesyngap1.org/calendar/million-dollar-bike-ride-2025/ Well done to Tavilla and Jones! We are over $221k Tavilla clears $160k for Sprint. https://donate.curesyngap1.org/campaign/sprint4syngap2025/c660255 Porter Jones and his friends William, Patrick, and Judson raised over $10k in doughnuts, this netted over $8k because people donated. Amazing and thank you to Krispy Kreme. https://donate.curesyngap1.org/event/sweets-for-syngap1/e678677 SRF PROFILES Vicky post in Mexico https://www.linkedin.com/posts/victoria-arteaga-26913433_diagnostico-epilepsia-syngap1-activity-7329725268003069953-R41P Vicky's Siblings Violeta and Lourdes, sisters to Amelia https://curesyngap1.org/syngap-siblings/ Harper Albrecht Wednesday Warrior #215 parents Ashley and Justin https://cureSYNGAP1.org/Warrior PREREGISTER FOR THE CURE SYNGAP1 CONFERENCE https://curesyngap1.org/calendar/cure-syngap1-conference-2025-hosted-by-srf/
The San Jose Hockey Now Podcast is sponsored by Bring Hockey Back! It's part 2 of a mega-2025 Draft Lottery mailbag! Part 2 is all about what the San Jose Sharks should do with the 2025 No. 2 pick. In case you missed it, Part 1 focused on how to improve the Sharks next year, especially on defense. https://youtu.be/LJPWjFPxZUg Let's get to the questions! Jeremy: What would it take to trade up to the No. 1 pick? (2:16) Nick Valderrama: Who would Keegan replace Sheng with? Is there a trade for the San Jose Sharks' No. 2 that we like? Sam: Thoughts about Martone? (18:02) Brad Fitzpatrick: Is Martone a much more serious possibility than we think? Austin Dias: How interested are teams around the NHL in the No. 2 pick? Ben: What does the package look like that would tempt Mike Grier to trade down? Matt Harrison: Who should the Sharks dangle for defensive help? The No. 2 pick? Which prospects? Astoverpix: Trade Musty for defensive help? Dylan Smallwood: Would you make this No. 2 pick/Noah Dobson trade with the New York Islanders? (34:54) GH: No. 2 pick for Owen Power, Rasmus Dahlin, or Bowen Byram? David: Will the San Jose Sharks make any jersey changes this off-season? Arch Mickel: What's the plan for Sam Dickinson? Beast: Offer Mitch Marner a short-term, max AAV contract? (52:48) Lincoln Race: Pitch for Marner? Boomer: Sheng's hockey background? Juan Rebollo: Do the San Jose Sharks pick more for need in 2026? Zeke: How can you tell if Mike Grier is excited? Should the Sharks target Anthony Stolarz or Joseph Woll? SwedeShark: How likely is it that the Sharks pick Victor Eklund? Joseph: How hard will it be for the Sharks to fill their holes via free agency? Tgraveline: How chaotic will this off-season be league-wide? Chris: San Jose Sharks' roster construction/needs next year? (1:12:43) Just Steve: Which teams do you think that the Sharks are likely to leapfrog in the standings next year? Matthias893: Keegan's favorite book on his bookshelf? Sheng's personal favorite basketball player? Fin Coe: Thoughts on Leo Sahlin Wallenius? James Barrett: What's the most valuable surplus in the San Jose Sharks' system? rphillips19: Where would Michael Misa and Matthew Schaefer be picked if they were in the 2023 Draft, 2024 Draft? Have all successful rebuilds actually drafted their top defensemen? Stephanie k: Is William Eklund the Sharks' most valuable (reasonable) trade piece? (1:37:53) Kyle J from Australia: Where would Sam Dickinson be ranked in the 2025 Draft? Chaz Marshall: Who goes to wing, Michael Misa or Will Smith? Should Misa stay in juniors, go to the NCAA, or the NHL next year? Anthony: How about trading the Dallas Stars' first for defensive help? Shaun Abuzalaf: Offer sheet Fabian Zetterlund?
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The White House has announced a new drug pricing policy that includes the revival of the most favored nations rule and extends to the private markets, leveraging the patent system, drug importation, and more. Meanwhile, Lilly's Zepbound has been found to have a superior benefit-risk ratio compared to Novo's Wegovy, BMS and Sanofi settle a Plavix lawsuit with Hawaii for $700 million, and biopharma companies are focusing on developing a cure for HIV as federal funding for related research is being cut. Sino Biological offers comprehensive solutions for autoimmune diseases, and Roche promises a $300 million investment in China production after a multibillion-dollar investment in the US. On the other hand, Lexeo and IGM have both announced significant layoffs. Novartis CEO has expressed concerns about Trump's pricing controls.Funding for HIV-related research and infrastructure is being cut by the Trump administration, leading biopharma companies like Gilead and Immunocore to focus on finding a cure for HIV. In the field of neurology, there is a need for more precise diagnostic tools to effectively treat neurodegenerative conditions. The new HHS vaccine requirement has been criticized by leading vaccine physician Paul Offit as potentially being anti-vaccine activism disguised as policy. Companies like Novartis, Bayer, and AstraZeneca are exploring new indications and innovations in radiopharmaceuticals, hoping to capitalize on a market that could reach $16 billion by 2033. The FDA has faced delays in reviewing certain drugs, while biotech stocks have fallen after the appointment of Vinay Prasad to succeed Marks at CBER. Vertex has decided to abandon AAV in the gene therapy space.Upcoming events include a webinar on surviving and thriving in the biotech downturn. Job opportunities in the biopharma industry include positions at Takeda, Daiichi Sankyo, and AbbVie. Heather McKenzie, senior editor at BioSpace, is open to suggestions for future coverage topics in neuroscience, oncology, cell & gene therapy, metabolic, or other areas.
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company's latest milestone—a successful £0.5 million fundraising to support a gene therapy trial in ageing dogs using SIRT6. Dr Leire explained that the funding was secured via a share subscription from a US-based longevity fund, with shares issued at market price and without a discount—what he described as a clear “vote of confidence in the company and its therapies.” Dr Leire explained that the funding was secured via a share subscription from a US-based longevity fund, with shares issued at market price and without a discount—what he described as a clear “vote of confidence in the company and its therapies.” The trial aims to demonstrate proof of concept in dogs, replicating promising results previously seen in mice. “It worked like magic in mice. We reasonably think that it will work likewise in dogs,” Leire stated. Unlike mice, however, dogs share environmental conditions with humans, making them a more relevant model for translation into human therapies. Leire also highlighted the commercial potential of targeting animal health, as it offers a shorter regulatory pathway compared to human applications. He confirmed that the trial has reached a key milestone: the randomisation of 24 senior dogs, aged over ten years, into four arms, including one control group and three treatment groups using different SIRT6 delivery methods. He also addressed ethical considerations, stating that the therapy does not involve genetic modification, and described the use of non-integrating gene therapy approaches, including naked DNA and AAV vectors. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel and enable notifications for future content. #GenflowBiosciences #GeneTherapy #SIRT6 #DogAgingTrial #LongevityResearch #BiotechFunding #AnimalHealth #AntiAging #Biotechnology #ClinicalTrials #LifeSciences #InvestingInBiotech #SeniorDogs
On hour two of Flames Talk, Pat Steinberg is joined by Eric Francis for a full hour to break down Matt Coronato's seven-year, $6.5 million AAV extension with the Calgary Flames. Pat and Eric dig into why the Flames prioritized locking up Coronato long-term, how the deal got done with a number starting with a six, and why it's a win for both the organization and the player. They also discuss what message it sends to see an American-born player commit to Calgary, and how high Coronato's ceiling could be as he enters the prime years of his career.(35:03) Later, Pat and Eric shift gears to Dustin Wolf and whether the Flames should aggressively pursue a long-term extension for the goaltender when he becomes eligible on July 1. The guys debate how Calgary could convince Wolf to sign, how much risk comes with term for a young netminder, and what kind of offer might get it done sooner rather than later.The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate. https://www.sportsnet.ca/960/flames-talk/
On this week's episode, we name and debate our Mount Rushmore for each position in the history of baseball. From there, we discuss the highest paid player (by AAV) at each spot on the diamond, the elimination of the buffer zone by umpires that has hitters and pitchers guessing the strike zone like never before, roster moves in Detroit, Texas, and Cincinnati, and which baseball players would be our top choices to enlist to be a part of our 100 player roster in a battle to the death against a gorilla.
On hour one of Flames Talk, Pat Steinberg is joined by Daily Faceoff's Frank Seravalli to dig into the early offseason priorities for the Calgary Flames. The guys talk about what Dustin Wolf's next contract could look like and whether Matt Coronato is a candidate for a long-term deal. They also hit on Rasmus Andersson's uncertain future, Rick Tocchet's Vancouver tenure coming to an end, Mike Sullivan's exit in Pittsburgh, and coaching possibilities across the NHL. Plus, Frank shares his thoughts on the Stars' dominance, the Oilers' outlook heading into Game 5, and the tight battle between Winnipeg and St. Louis.(26:55) Pat and Aaron Vickers take a hard look at Morgan Frost — maybe the toughest RFA for Calgary to figure out this summer. Frost had 12 points in 32 games after being acquired from the Flyers, and now the team has to decide what he is, what he could still become, and what kind of deal makes sense. With Frost one year from UFA eligibility and turning 26 soon, the guys debate whether a four-year, $4 million AAV contract is a realistic target. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate. https://www.sportsnet.ca/960/flames-talk/
In today's pod we break down the Cowboys future and in particular why it scares me. They are in a tough position to try to go from being a good team when healthy - to a great team. And it makes matters a lot more difficult when they are paying a quarterback an AAV of $60M per year along with a new head coach. I hope you enjoy! TWITTER: https://mobile.twitter.com/FBallAnalysisYT DISCORD: https://discord.gg/XAjBEcGVbH TIKTOK: https://vm.tiktok.com/ZMe5NbVa7/ Welcome to the Football Analysis Podcast! Subscribe for all NFL related content! Please drop 5 star rating if you enjoyed the pod as all support is very much appreciated! Thanks for listening! #nfl #nflfootball #football #nfldraft #dallascowboys #cowboys Support Us By Supporting Our Sponsors! UNDERDOG Fantasy: Up To $1,000 Bonus Cash When You Make Your First Deposit: https://play.underdogfantasy.com/p-football-analysis Gametime: Download the Gametime app (https://gametime.co/) and redeem code ANALYSIS for $20 off your first purchase (terms apply)
We love to hear from our listeners. Send us a message.In this episode of Cell & Gene: The Podcast, Host Erin Harris dives into the world of retinal gene therapy with Kenji Fujita, M.D., Chief Medical Officer of Atsena Therapeutics. Atsena develops treatments for inherited retinal diseases, including X-linked retinoschisis (XLRS), a rare genetic condition that currently has no FDA-approved therapy. They talk through the impact of XLRS on patients, the challenges of gene delivery to the retina, and how Atsena's AAV vector technology is designed to overcome these hurdles. They also discuss the significance of the Fast Track designation recently granted to Atsena's XLRS program, the role of patient advocacy in rare disease research, and the key milestones to watch for in the months ahead.Subscribe to the podcast!Apple | Spotify | YouTube
We are building up to the deadline! We discuss Chicago trading Petr Mrazek and Craig Smith in exchange for Joe Veleno to the Red Wings, Charlie Coyle is off to Colorado for Casey Mittelstadt who is off to Boston, and Wyatt Johnston signs an extension with Dallas for 5 years at $8.4 AAV!SHOUTOUT TO OUR SPONSORS!!
Audio roundup of selected biopharma industry content from Scrip over the business week ended 28 February 2025. In this episode: which big companies face the least LOE hit?; IPOs rise in 2024; Pfizer cuts last AAV gene therapy program; balance and focus suggested for globalizing Chinese firms; and Scrip Asks on therapeutic area advances. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-4RXPQH4B5NBJ3AM7SFMPROUJ2U/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things
In today's over/under Casey Warner sets the lines on Lightning end of season win total, Nikita Kucherov's point total, how far is a "long drive", Matthew Stafford's new deal AAV and Lakers end of season win total.
Fantasy Baseball Live – February 16 2025 @ 3 pm ETSegment 1 – News and Notes1.Alex Bregman finally signed with Boston for three years and $120 million. While it wasn't a lengthy deal, the AAV of $40 is tremendous. Of course, he can opt-out after each year.a.Let's examine the Boston Red Sox lineup to see what shakes out given that there is a strong possibility he plays second.2.Many thought the Padres were sellers, but they signed Nick Pivetta to a four-year, $55 million contract.a.He had a solid season in 2024 – 172 Ks in 142 IP with a 4.14 ERA. The data says there is more in the tank, and Petco will help with his flyball tendencies—what are your thoughts?Segment 2 – Outfield Preview1.How are you approaching this position for your upcoming drafts?2.We will break down the top 30 to 45 in detail. Then, go through 30 or so in less detail. We will end by jumping around the remaining ranked players.3.Which player not in the Top 10 has a chance to emerge there next season?4.Which Top 10 player will not be there next season?5.Give me a couple of sleepers6.Give me one, maybe two guys you are just going to avoid drafting?
Fantasy Baseball Live – February 16 2025 @ 3 pm ETSegment 1 – News and Notes1.Alex Bregman finally signed with Boston for three years and $120 million. While it wasn't a lengthy deal, the AAV of $40 is tremendous. Of course, he can opt-out after each year.a.Let's examine the Boston Red Sox lineup to see what shakes out given that there is a strong possibility he plays second.2.Many thought the Padres were sellers, but they signed Nick Pivetta to a four-year, $55 million contract.a.He had a solid season in 2024 – 172 Ks in 142 IP with a 4.14 ERA. The data says there is more in the tank, and Petco will help with his flyball tendencies—what are your thoughts?Segment 2 – Outfield Preview1.How are you approaching this position for your upcoming drafts?2.We will break down the top 30 to 45 in detail. Then, go through 30 or so in less detail. We will end by jumping around the remaining ranked players.3.Which player not in the Top 10 has a chance to emerge there next season?4.Which Top 10 player will not be there next season?5.Give me a couple of sleepers6.Give me one, maybe two guys you are just going to avoid drafting?
CME credits: 0.75 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/implementing-the-soc-induction-therapies-in-aav/32349/ Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes early diagnosis of this rare, autoimmune disease important for developing an effective treatment plan and personalized treatment selection a key success factor in the optimization of patient care.
CME credits: 0.75 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-aav-outcomes-maintenance-therapies/32350/ Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes early diagnosis of this rare, autoimmune disease important for developing an effective treatment plan and personalized treatment selection a key success factor in the optimization of patient care.
CME credits: 0.75 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/elevating-care-for-patients-with-severe-renal-disease-in-aav/32352/ Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes early diagnosis of this rare, autoimmune disease important for developing an effective treatment plan and personalized treatment selection a key success factor in the optimization of patient care.
CME credits: 0.75 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-patients-with-aav-in-the-rheumatology-clinic/32353/ Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes early diagnosis of this rare, autoimmune disease important for developing an effective treatment plan and personalized treatment selection a key success factor in the optimization of patient care.
SEGMENT - After years of passiveness from Red Sox ownership, the Sox have agreed to a 3-year deal with 3B Alex Bregman carrying an AAV of $40 million. But Jones is skeptical to say that the Sox are fully back
- Alex Bregman and the Boston Red Sox agree on a three-year, $120 million contract- $40 AAV a season- Alex Bregman's tenure in a Astros uniform- Clubhouse leader- Fenway Park favors Breggy- What's next for Houston?- Astros have their guy at third base- Does Bregman not being in Houston hurt their chances at winning the division- Much, much, more!YouTube link: https://youtube.com/live/4gCdf54z3jsHave you subscribed to the Full Seam Ahead YouTube Channel yet? Make sure to hit that subscribe button and hit that notification bell to stay up to date on all the latest Astros news, rumors, interviews, live streams, and much more all year long!
Alex and Facci discuss Alex Len not signing with Indiana, and the Pacers bringing in Jahlil Okafor on a 10-day contract. Then, they answer Pt. 1 of the Mailbag Podcast. 1). Northeast Nightmare over on Blue Sky has 3 questions for us! A). First, rank which opponent you'd like to see Indiana face in the first round out of Milwaukee, Detroit, Miami and Orlando. 1st by matchup, 2nd by storyline. B). Do you think Myles Turner will credit the Pacers $10M towards his next contract since Indiana did him a service and paid him nearly $30M a year on the last renegotiation and extension? C). Will the Pacers use Isaiah Jackson's disabled player exception to sign Alex Len? Is there any benefit towards that? (Mentioned James Johnson needing to be released, but this is why they traded Wiseman). 2). Aaron M — THE GOVERNOR of the Setting The Pace Fan Club Do you think the best chance for the Pacers to win an NBA title is actually continuity, or is that just a word they throw around? This is considering the odds the Pacers win the #1 pick are zero like they appear to be. 3). Chuck and Jamie — THE OG FANS OF THE WEEK! At the halfway point: What has been your biggest surprise this season? Who has made the most improvements? Who/what has been the most disappointing? One thing you hope to see in the second half of the season? 4). Roosters — the President of the Setting The Pace Fan Club In your estimations what are the chances Herb goes into the tax this offseason to sign Myles to a long term deal? Also, what would you be willing to sign him to if it were up to you? Personally I'd try to get him for 5/100 and offer him a NTC. Knowing may have to go higher AAV. Learn more about your ad choices. Visit podcastchoices.com/adchoices
James Anderson and seasoned NFBC Auction player Marc Winokur go through some recent high-stakes auctions and which players are more in-demand by auction players than by snake draft players! 00:00 Intro 01:20 Early Auctioning 13:10 Closers in Auctions 20:30 Buying Skubal 28:00 Old, boring SP2s 32:50 What A Cheap Offense Looks Like 38:00 Zero-Dollar Players 40:55 Stacking 46:00 Top Hitters Overpriced 50:00 AAV vs. ADP 54:20 Outfielders 01:02:30 Catchers 01:05:10 First Base 01:06:00 Second Base 01:13:30 Shortstop 01:17:35 Pitcher Learn more about your ad choices. Visit podcastchoices.com/adchoices
James Anderson and seasoned NFBC Auction player Marc Winokur go through some recent high-stakes auctions and which players are more in-demand by auction players than by snake draft players! 00:00 Intro 01:20 Early Auctioning 13:10 Closers in Auctions 20:30 Buying Skubal 28:00 Old, boring SP2s 32:50 What A Cheap Offense Looks Like 38:00 Zero-Dollar Players 40:55 Stacking 46:00 Top Hitters Overpriced 50:00 AAV vs. ADP 54:20 Outfielders 01:02:30 Catchers 01:05:10 First Base 01:06:00 Second Base 01:13:30 Shortstop 01:17:35 Pitcher Learn more about your ad choices. Visit podcastchoices.com/adchoices
Summary: This week on The Genetics Podcast, Patrick is joined by Eric Adler, Chief Medical Officer and Head of Research at Lexeo Therapeutics and Professor of Medicine at University of California San Diego. Eric shares his experience with genetic cardiomyopathy and his work on gene therapy for Danon disease, drawing from both clinical and research perspectives. Additionally, he explores the evolution of the field and the broader challenges faced by cardiovascular patients. Show Notes: 0:00 Intro to The Genetics Podcast 01:00 Welcome to Eric and his efforts in cardiomyopathy at the bench and bedside 03:32 How modeling genetic diseases using pluripotent stem cells lead Eric to studying Danon disease 04:50 Pivoting from basic to translational research using adeno-associated viruses (AAV)-based gene therapy 07:58 Uncovering genetic cardiomyopathies that were misdiagnosed as idiopathic cardiomyopathy 09:55 Treatment, screening, and penetrance of Danon disease 12:30 Recent successes and remaining challenges in cardiovascular disease 19:47 Battling distrust in the medical profession 21:55 Preventative therapy using APOE2 for patients at risk of early Alzheimer's 25:15 Motivations behind and advantages of Eric's patient-centered approach to therapeutics 27:24 Balancing regulatory requirements for protocols versus patient needs 29:49 The importance of committed clinical partners for successful trial execution 36:08 Eric's passion for cooking and how he won a cooking competition 39:02 Closing remarks and Lexeo Therapeutics' aims for 2025 Find out more Lexeo Therapeutics (https://www.lexeotx.com/) Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
In a record setting performance, Alex Nedeljkovic scores a goal and adds an assist, the first time an NHL goalie has managed that feat. Meanwhile, did Connor McDavid escape discipline for a sneaky elbow? Mike continues to be flummoxed by the unwillingness of Leafs fans to enjoy this season. Listen Here: Apple Podcasts Direct MP3 iHeart Radio Title Player Don Marcotte News Ndeljkovic scores - 16th goalie to score, 11th to shoot it https://www.nhl.com/news/nhl-goalie-goals-all-time-313758920 Took a hit to make the play! Also had an assist - 1st time ever goal and assist Scored 2 in AHL and 1 in ECHL - 1st ever McDavid chicken wing - no fine or suspension - what do you think? https://youtu.be/NX8P28Fjats?si=b8ALcjbaZgyl7BIX Oilers sign Klingberg - $1.75 AAV - 32 yrs old - gets $1MM - $350k bonus plus salary - hasn't played since Nov 2023 Oilers beat Kings, Wild and Avalanche this week - were done 3-0 to Avs and came back. Matthews continues to score despite Leafs struggles lately Rumours that Marchand might be on the trade block - last year of 8 yr contract - $6MM - 36 yrs - if Bruins fall out of playoffs will they move him? Guess the 5th Columbus Blue Jackets - where did they come from? Last 10 - 8-10-0 6W in a row Currently in 1st wildcard in East Fancies GF% 51% (11) xGF% 48.71% (25) SH% 10.03% (3) SV% (25) Since Dec 1 GF% 51.55% (12) xGF 45% (28) SH% 9.8 (8) SV% 91.12 (17) Since Dec 22 - have scored a PPG per game Have been on a hot streak but nothing to indicate it's real - Schedule has been pretty soft over this span Connections - Last Week - lubes, swing, flase, teardrops - anagrams of NHL team names This Week - Claude Julien, Alain Vigneault, Pat Burns, Benoit Groulx Crazy Stat - DOPeS - Tsyplakov 3 games hit to head https://www.nhl.com/news/new-york-islanders-maxim-tsyplakov-suspended-3-games
Today's episode takes us into crucial territory where science meets ethics in gene therapy development. Following our recent compelling conversation with Ben Hurlbut on germline genetic editing, we're diving deeper into the ethical dimensions of bringing new treatments to patients. We'll explore two critical challenges that development teams face: determining the initial dose for therapy and establishing acceptable parameters for off-target effects before clinical testing. While these decisions are grounded in scientific data, they carry profound ethical implications – especially considering that AAV-based therapies are currently "one and done" treatments, where redosing isn't yet possible. Thomas Wechsler, chair of the ASGCT Ethics Committee, will join us to help us navigate the technical and ethical dimensions of these crucial decisions. His unique perspective will help us understand how teams balance scientific rigor with ethical responsibility when introducing new therapies to the clinic. Music by: https://www.steven-obrien.net/--------------------------Bright New Morning - Steven O'Brien (Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.
While we still wait for Teoscar Hernàndez to return to LA, a new update on Corbin Burnes' market could be great news for the Dodgers. According to Ken Rosenthal, the 2021 NL Cy Young award winner may be open to a short-term, high AAV deal this winter - something right up Andrew Friedman's alley. I discuss the latest news and look at the Dodgers starting pitching and where it stands heading into the new year. Plus other Dodgers news and rumors; and voicemails on another edition of the All Dodgers Podcast! Tube in all offseason long! Leave a voicemail or text the Friend of the Show hotline!
Eno and DVR are joined by The Athletic's Ken Rosenthal to discuss Wednesday's trade that sent Garrett Crochet to the Red Sox, the importance of a lower AAV in Max Fried's deal with the Yankees, and an active Winter Meetings.Plus, they are joined by Esteban Navarro Garaiz of Zelus, Marlins Director of Pitching Bill Hezel, and former big leaguer Jed Lowrie to discuss each of their paths into baseball.Rundown0:00 Intro Starts13:31 Esteban Navarro Garaiz of Joins the Show34:52 Bill Hezel Joins the Show52:11 Jed Lowrie Joins the Show1:07:30 Goodbye from Dallas!Follow Eno on Bluesky: @enosarris.bsky.socialFollow DVR on Bluesky: @dvr.bsky.sociale-mail: ratesandbarrels@gmail.comJoin our Discord: https://discord.gg/FyBa9f3wFeSubscribe to The Athletic: theathletic.com/ratesandbarrelsHosts: Derek VanRiper & Eno SarrisWith: Esteban Navarro Garaiz, Bill Hezel & Jed LowrieProducer: Brian Smith Hosted on Acast. See acast.com/privacy for more information.
Eno and DVR are joined by The Athletic's Ken Rosenthal to discuss Wednesday's trade that sent Garrett Crochet to the Red Sox, the importance of a lower AAV in Max Fried's deal with the Yankees, and an active Winter Meetings.Plus, they are joined by Esteban Navarro Garaiz of Zelus, Marlins Director of Pitching Bill Hezel, and former big leaguer Jed Lowrie to discuss each of their paths into baseball. Rundown 0:00 Intro Starts 13:31 Esteban Navarro Garaiz of Joins the Show 34:52 Bill Hezel Joins the Show 52:11 Jed Lowrie Joins the Show 1:07:30 Goodbye from Dallas! Follow Eno on Bluesky: @enosarris.bsky.social Follow DVR on Bluesky: @dvr.bsky.social e-mail: ratesandbarrels@gmail.com Join our Discord: https://discord.gg/FyBa9f3wFe Subscribe to The Athletic: theathletic.com/ratesandbarrels Hosts: Derek VanRiper & Eno Sarris With: Esteban Navarro Garaiz, Bill Hezel & Jed Lowrie Producer: Brian Smith Learn more about your ad choices. Visit megaphone.fm/adchoices
Rundown [Intro] Sox Machine will be heading on the road to Dallas, Texas covering the 2024 Winter Meetings. The crew shares their favorite memories of past Winter Meetings and what to expect concerning coverage. [13:09] The Chicago White Sox still haven't officially announced their 2025 coaching staff, which creates confusion as to why and raises the open question of how new manager Will Venable isn't bringing more new faces to the clubhouse. [27:01] Garrett Crochet will garner attention in Dallas, and James Fegan is hearing about the possibility of another three-team trade format [36:51] Frankie Montas and Matthew Boyd signed new deals with an AAV greater than $14 million despite recent injuries and poor performance. Is it time to reconsider how we calculate WAR/$ for pitchers as the free agency market continues to inflate? [46:03] There will be another vote for Hall-of-Fame as Dick Allen gets another crack. Will he finally make it, and why John Donaldson's contributions shouldn't be ignored. [1:00:00] Making fun of Rob Manfred's new rule proposal, the Rule 5 Draft for White Sox, and MLB Draft Lottery results Learn more about your ad choices. Visit podcastchoices.com/adchoices
Watch Off the Bench Presented by UDF with Chatterbox Sports Monday-Friday 10 a.m. - 12 p.m. LIVE on the Chatterbox Sports YouTube channel. SUBSCRIBE to the channel to ensure you never miss a thing. #rulethejungle #cincinnatibengals #nfl #nflfootball #nflnews #nflhighlights #mlbtheshow #mlb #mlbhotstove #bengals #bearcats #cincinnati #joeburrow #mlbbhighlights #atobttr #whodeynation #fccincinnati #mls #nflseason #cincinnatireds #reds #newenglandpatriots #baltimoreravens #kansascitychiefs ⏩ Watch More: ◼ Bengals MUST WIN in Kansas City Week 2 Preview | Chatterbox Bengals - https://www.youtube.com/live/aZtseW9lpH0?si=L5ZDcVwA2RZFg5zm ◼ Do Reds Fans Forgive Noelvi Marte? | CBox Man On The Street - https://youtu.be/Rwh4PudzJhs ◼ Asking Strangers if Cincinnati Reds David Bell Should be Fired | CBox Man on the Street - https://youtu.be/3Ye-HjJdmmQ ◼ NCAA EA COLLEGE FOOTBALL 25 GAMEPLAY REACTION! | CBox Reacts - https://youtu.be/hXQwjMcD244 Music from #InAudio: https://inaudio.org/ Riff Rock PODCAST LINKS: Apple: https://apple.co/3QsyY1C Spotify: https://spoti.fi/3KWJcWR Google Podcasts: https://bit.ly/3RwZ9We Stitcher: https://bit.ly/3BqqmEg iHeart Radio: https://bit.ly/3BtowTm Amazon: https://amzn.to/3Db8Rcw CHATTERBOX LINKS: Chatterbox Reds: https://linktr.ee/chatterboxreds Chatterbox Bearcats: https://chatterboxbearcats.podbean.com/ Chatterbox Bengals: https://www.youtube.com/playlist?list=PLjPJjEFaBD7WtWXJbcB_g2xYu7ST276R7 Chatterbox Clicker (Bengals Film Breakdown with Coach Kyle Caskey): https://www.youtube.com/playlist?list=PLjPJjEFaBD7V9GfyT1tl6M1dWQtQ9730Z The Chatter Podcast: https://queencitychatter.podbean.com/ Chatterbox Store: https://www.chatterboxsports.com/store TikTok: https://www.tiktok.com/@cboxsports Instagram: https://www.instagram.com/cboxsports/ Twitter: https://twitter.com/CBoxSports Facebook: https://www.facebook.com/cboxsports The Gangs Socials - Twitter: https://twitter.com/ThomBrennamanTV Twitter: https://twitter.com/ReidMausRadio Twitter: https://twitter.com/etrain513 Twitter: https://twitter.com/CBoxCasey Twitter: https://twitter.com/CBoxTrace Twitter: https://twitter.com/Nicholaspkirby Twitter: https://x.com/1410Kinner We Cover this Story written by Drew Koch from Blog Red Machine The internet was abuzz throughout Reds Country on Monday night with unconfirmed reports that a former All-Star could be on his way back to the city of Cincinnati. According to Mark C. Healey, Jesse Winker may be close to a deal with the Cincinnati Reds. That's certainly not the oddest thing that Reds fans have heard this offseason, and to a certain extent, reuniting with Winker would actually make a lot of sense. After two down years with the Seattle Mariners and Milwaukee Brewers, Winker resurrected his career in 2024 with stops in Washington and New York. Winker began the 2024 season with the Washington Nationals and hit .257/.374/.419 with 11 home runs and 45 RBI. The former first-round pick was then dealt to the New York Mets at the MLB trade deadline and put up a .243/.318/.365 slash line in Queens. Combined, Winker posted a .764 OPS last season and was 7-for-24 with three extra-base hits during his postseason run with the Mets. Reds Free Agency: Jesse Winker's potential return to Cincinnati has the fanbase split On the one hand, adding a power-hitter to the middle of the lineup would be a plus. The past three seasons, Winker slugged just .354, but during his five-year run in Cincinnati, Winker's slugging percentage was .504 with a 129 OPS+. Winker appeared to get back on track last season in terms of his power numbers, and the Buffalo native has always had a terrific eye at the dish. Winker was ranked in the 96th percentile last season is terms of chase rate and walk rate according to Baseball Savant. With Jonathan India now in Kansas City and Joey Votto enjoying retirement, the Reds don't have that reliable, patient hitter in the lineup who's able to draw walks and reach base with regularity. Adding a veteran like Winker whose knowledge of the strike zone is among the best in the league would undoubtedly offer an upgrade to the Reds lineup. But there's a downside to signing Winker, and that comes on the other side of the ball. Though he can play in the outfield, Winker is among the worst defenders in Major League Baseball. Last season, while splitting time as a designated hitter, Winker was worth -11 outs above average and -41 OAA for his career. For a club looking to upgrade their defense, adding Winker would seem to be a huge mistake. Whe 31-year-old also has noticeable lefty-right splits that would likely limit him to a platoon role. Last season, Winker hit just .236/.337/.337 against left-handed pitching while posting a .258/.366/.422 slash line against right-handers. Do the Reds really need another defensive liability who's also likely to sit against lefties? From a payroll standpoint, adding Winker makes sense. Few teams are likely to hand over more than a two-year deal in order to sign the longtime Reds outfielder, and the average annual value (AAV) would probably come in at less than $10 million. That's well within the scope of what the Reds could afford. There's definitely reason to believe that a reunion with Winker could work, but only if there are more moves to follow. At least Reds fans know that Winker hates Milwaukee, so he's got that going for him. Stay tuned, Reds fans. This could get interesting.
In this episode of Urban Valor, Marine veteran Brandon Hagar, a former U.S. Marine Infantryman (2017-2021, E4/Corporal), shares the tragic story of the Amphibious Assault Vehicle (AAV) mishap that resulted in the deaths of 8 Marines and 1 Navy Corpsman. Brandon, from Turlock, CA, opens up about the toxic leadership within his command, describing how constant micromanagement and leadership failures contributed to this tragic event. The AAV sinking marked one of the darkest moments in his military career, with Brandon reflecting on how it highlighted severe Marine Corps leadership issues.Brandon's journey didn't end there. Despite the trauma of his enlistment, he found a new purpose in life after leaving the Marines. Today, he helps veterans rediscover their purpose through nutrition coaching and powerlifting, supporting those struggling with their post-military lives.
TWiV reviews continuing expansion of poliovirus type 2, removal of influenza B/Yamagata from the vaccine, Nobel Prize for miRNAs, protective immune response with a adenovirus-associated virus vector expressing a computationally designed hemagglutinin, and viral gene drive during herpes simplex 1 infection in mice. Hosts: Vincent Racaniello, Alan Dove, Rich Condit, Kathy Spindler, and Brianne Barker Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode MicrobeTV Discord Server Continued expansion of type 2 poliovirus (reliefweb) No more polio case map at polioeradication.org B/Yamagata removed from flu vaccine (NPR) Nobel Prizes for miRNA (ScienceInsider) AAV-vectored influenza vaccine (J Virol) Herpesvirus type 1 gene drive in mice (Nat Commun) Timestamps by Jolene. Thanks! Weekly Picks Brianne – Virus and Vaccines Information Page from NIH All of Us Research Program Kathy – For a Pivotal Vaccine: Trial, Error and Two Young Lives Rich – October 17 2024 APOD: The Clipper and the Comet Alan – Opening a deep-sea vent with a crowbar Vincent – The expanding world of neuroscience Listener Pick Jason – Solar eclipse on Mars and Polaris Program and their Harmony of Resilience Ryan – New York's childhood vaccine coverage remains high Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.
Tuesday, October 22, 2024 First Principles Genetic disease means that gene broken since conception. Novel medicines are possible ways to fix the gene - Genetic Therapies (ASO &/or AAV), this is recent, before now, kids with these diseases were a “go home and love them” situation. These are delivered via spinal tap or directly to the brain in leading medical centers. First though, regulators must approve. Our job Develop medicines or get industry to - This is happening see Pipeline Get regulators to approve trials Get medical centers up to speed on SYNGAP1-Related Disorders (SRD) What we are building on CHOP ENDD funded externally (see #S10e92) and replicating what was built for STXBP1, check last week's webinar https://curesyngap1.org/resources/webinars/93-endd-chop-2024-syngap1/ Rare-X platform for PRO collection Regulatory pathway being made clearer every day by Stoke (Dravet), Praxis (SCN2A), Ionis (many) all of whom are working on SYNGAP1 as well. What we are asking for We need to raise at least $500k (3rd site), preferably $1.13M (ProMMiS) Make your largest gift ever to SRF Fundraise with friends and family ACES is now ProMMiS, who knew ACE meant Adverse Childhood Event, not us. Key slides: S1 Path to Treatment | 2024 (09.27.24) 1. Why Now? Why is it time to go from bench to bedside (research to clinical)? At least 10 companies on our pipeline not to mention multiple small molecule efforts We have limited resources – so the focus has to transition, clinical funding first. CHOP Gift is 1 year down… 2. Why NHS?Understand SYNGAP1 better, go beyond Vlaskamp 2019 and Wiltrout 2024, see #S10e105 FYI at CHOP, as I shared in #S10e151, at year 1, we are at – 86 (Visits) + 10 (new scheduled) + 19 (2nd) + 4 (3rd) + 22 (follow up) Learn what to measure in clinical trials for SRD, remember our seizures are challenging Ideally we develop a Synthetic Control Arm if we use GCP Why top shelf? We need institutions the FDA will take seriously and our children are very complex requiring experienced clinicians. 3. Why Multidisciplinary. Neuro, Psych, Genetics, PT, ST, OT, GI, Sleep, ENT, Ortho. Beyond the sheer burden of getting our kids out and about for multiple appointments the coordination by a parent is almost impossible. 4. Why Multisite/3 sites?Replicable/scalable required by regulators Accessibility (not primary reason) Establish more locations where trials will be managed Laying a foundation for a national self-sustaining network 3 is the minimum, look at STARR or Angelman, both had/ve 4. 5. How and why so fast? Because we can. Time is Brain. Following a well trodden path SMA, Rett, Angelman, Dravet, but we are moving FASTER. 6. Does the industry really care? We are next there are so so many behind us, eager to take the resources we have access to today. Market size (Per our Census 425 US/1500 global is tip of iceberg) Multiple players reassuring each other Relatively strong amount of scientific and clinical research Haploinsufficiency (like Dravet – STOKE) – so relatively easy 7. Expensive? No. Clinical Research is more expensive than basic scientific research. Leveraging CHOP and Rare-X, setting up required networks to prepare for clinical trials. It's time. 8. Why Bother/Help? Now is the time for SYNGAP1, we miss it at our peril. Sure, once in these places we will still see our patients, but the study, the support and the focus may pass. Our kids don't die, regardless of patient age, what we are doing can change their future and that of their loved ones and caregivers. If not us, then who? It is a rare exception when a non-family member gives a gift, and it is always because a family member asked. We must ask. 9. What can I do? Donate to, share, join our Coast2Coast Clinics Challenge – two SYNGAP1 Squads in West and East – it's critical $500k goal by end of 2024; more than $1M needed just for the SYNGAP1ProMMiS. So far, donations from $25 to $25,000 – each and every contribution matters. This requires our entire S1 network to solicit family, friends, work colleagues, companies, etc. to contribute. Many causes out there – why not ours? Syngap.Fund/C2C https://Syngap.Fund/C2C > https://secure.givelively.org/donate/syngap-research-fund-incorporated/coast2coast-clinics-challenge Two teams: https://Syngap.Fund/West & https://Syngap.Fund/East
MORITZ SEIDER HAS SIGNED! Steve Yzerman locks up the remaining pillar of the Detroit Red Wings core and decides that the Winged Wheel Podcast offseason ends a week early! Tune in as we break down the huge news of Moritz Seider's 7 year, 8.55 million AAV contract to keep him in Hockeytown long term: overall value, how it compares to the likes of Faber, Sanderson, Power, and others, where he stacks up among the highest paid defensemen in the league like Makar and Dahlin, how the 7 vs. 8 year deal staggers him from Lucas Raymond and matches him with Dylan Larkin, what to expect from him in the future, whether Simon Edvinsson or Ben Chiarot can act as a support moving forward in Derek Lalonde's system, & more (3:45). After that, we discuss Detroit's playoffs and Stanley Cup window, what Steve Yzerman has to do to add to the core 3 plus Kane, Tarasenko, DeBrincat, Johansson, Danielson, Mazur, Sandin Pellikka, Brandsegg-Nygard, Cossa, & others, & whether they need a superstar like Marner or Rantanen (36:15). Next, a quick update on Detroit Red Wings Training Camp in Traverse City (50:15), as well as NHL news (including Crosby's deal, expansion, Utah, & more) (53:00) before we take your questions & comments in our Overtime segment (1:00:05) - enjoy the show! Head over to wingedwheelpodcast.com to find all the ways to listen, how to support the show, and so much more! Max's Articles: https://www.nytimes.com/athletic/5579280/2024/09/19/red-wings-moritz-seider-contract-extension/ https://www.nytimes.com/athletic/5779754/2024/09/19/red-wings-training-camp-seider-berggren-kane/ FACTOR MEALS: Go to FactorMeals.com/WingedWheel50 to get 50% off your first box plus 20% off your next month while your subscription is active! #ad
LUCAS RAYMOND IS STAYING IN HOCKEYTOWN FOR 8 MORE YEARS! Tune into this MASSIVE episode (which features Max Bultman of The Athletic Detroit, new contributor to the Winged Wheel Podcast) as we discuss the extremely well-timed news of Lucas Raymond's 8 year, $8,075,000 AAV contract extension that Steve Yzerman locked in: overall value, what this means for Raymond's future, how he compares to Seth Jarvis and Tim Stutzle, how this works for the Detroit Red Wings salary cap now and in the future, expectations for Raymond alongside Larkin, Patrick Kane, Alex DeBrincat, Tarasenko, Compher, & others, & SO much more (3:30). We then discuss Jonatan Berggren's 1 year contract at $825k, what he needs to do to crack Derek Lalonde's Red Wings roster, comparisons to Sprong, & more (25:50). Next, the elephant in the room: what does this mean for Moritz Seider's contract? Is it soon to follow? Will he take up all (or more) of Detroit's remaining cap space, surpass Larkin, or sign in time to make training camp in Traverse City? (35:25) Finally, Max Bultman provides and update from the Prospects Tournament, including thoughts on Nate Danielson, Michael Brandsegg-Nygard, Finnie, & plenty more (52:45) before we take your questions & comments in our Overtime segment (1:04:30) - enjoy the show! Head over to wingedwheelpodcast.com to find all the ways to listen, how to support the show, and so much more! Max's Articles: https://www.nytimes.com/athletic/5767668/2024/09/16/red-wings-prospect-tournament-michael-brandsegg-nygard/ https://www.nytimes.com/athletic/5579464/2024/09/16/red-wings-lucas-raymond-contract-extension/ FACTOR MEALS: Go to FactorMeals.com/WingedWheel50 to get 50% off your first box plus 20% off your next month while your subscription is active! #ad
The Detroit Red Wings are not far away from hitting the ice for training camp in Traverse City, and Moritz Seider, Lucas Raymond, and Jonatan Berggren are still unsigned. Tune in as we start by discussing updates (or lack thereof) on Hockeytown's unsigned RFAs, whether there's anything to be concerned about with Raymond or Seider, how this compares to the Larkin or DeBrincat situations, Steve Yzerman's negotiation tactics across the board (3:55), where Berggren's contract fits in, and lots more (22:50). After that, Leon Draisaitl's eye-watering $14 million dollar AAV contract, how this impacts McDavid & Bouchard, & stacks up to Matthews, MacKinnon, & other superstars, & whether Edmonton is headed for a Leafs-like situation (with Marner potentially on the outs) (26:55). Also, updates on Zadina & Kubalik, thoughts on Crosby's final phase, Ducks and Utah jerseys, & lots more (46:50) before we take your questions & comments in our Overtime segment (57:35) - enjoy the show! Head over to wingedwheelpodcast.com to find all the ways to listen, how to support the show, and so much more! HelloFresh: America's # Meal Kit. For FREE breakfast for life, go to HelloFresh.com/FreeWingedWheel. (One free breakfast item per box while subscription is active). #ad
Our heartfelt condolences go out to the families of Johnny Gaudreau and Matthew Gaudreau after their tragic passing. (0:00) We start this episode by discussing Seth Jarvis' new contract with the Carolina Hurricanes and the strange "new" deferral that brings the AAV down (4:15) before discussing how this might compare to Lucas Raymond's next contract & how Steve Yzerman might use it to set a price for both him and Moritz Seider (and whether he can keep them under Dylan Larkin's AAV) (3:15). After that, thoughts on Hockeytown's reported interest (alongside the Leafs) in former star Max Pacioretty before news & updates on Marco Kasper and Michael Brandsegg-Nygard in their Olympic qualification efforts, as well as Red Savage, Austin Watson, & more (23:00). Next, thoughts on Detroit being ranked 14th by the Athletic in their U23/Pipeline rankings, & whether Detroit truly lacks stars or superstars (30:15). Finally, NHL news including Jeremy Swayman's contract demands, Nick Cousins joining the Ottawa Senators, the AHL's neck protection rule, & more (44:15) before we take your questions and comments in our Overtime segment (50:35) - enjoy! Head over to wingedwheelpodcast.com to find all the ways to listen, how to support the show, and so much more! PuckPedia Deferral: https://puckpedia.com/salary-cap/deferred Support Matthew Gaudreau's family: https://www.gofundme.com/f/support-madeline-and-baby-tripp-after-tragedy This episode is brought to you by BetterHelp. Give online therapy a try at betterhelp.com/wingedwheel and get on your way to being your best self. #ad HelloFresh: America's # Meal Kit. For FREE breakfast for life, go to HelloFresh.com/FreeWingedWheel. (One free breakfast item per box while subscription is active). #ad
© 2020-2025 Ivy Podcast Discovery LLC
